CVS Health Corp is not a strong buy for a beginner, long-term investor at this moment. While the company demonstrates strong financial growth and has positive long-term prospects, the lack of immediate positive trading signals, mixed analyst sentiment, and potential Medicare Advantage headwinds suggest waiting for more clarity or a better entry point.

Technical Analysis

The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 58.524, and moving averages are converging, showing no strong directional bias. The stock is trading near its pivot level of 76.615, with resistance at 79.224 and support at 74.006.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Revenue and net income showed significant YoY growth in Q4
Analysts highlight CVS's diversification and potential for upward revisions in Medicare Advantage rates.
Positive updates from the investor day, including mid-teens earnings growth guidance through 2028.

Neutral/Negative Catalysts

Medicare Advantage reimbursement rate uncertainty could impact future revenue.
Stock has a 60% chance of declining in the short term based on historical patterns.
Gross margin dropped YoY, indicating potential cost pressures.

Financial Performance

In Q4 2025, revenue increased by 8.17% YoY to $105.69B, net income surged by 79.01% YoY to $2.94B, and EPS rose by 76.15% YoY to 2.29. However, gross margin dropped by 2.73% YoY to 12.84.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are generally positive, with multiple Buy ratings and price targets ranging from $87 to $101. However, recent downgrades in price targets reflect concerns over Medicare Advantage reimbursement rates.

17 Analyst Rating

Wall Street analysts forecast CVS stock price to rise

16 Buy

1 Hold

0 Sell

Strong Buy

Current: 79.900

Low

Averages

96.71

High

105

Current: 79.900

Low

Averages

96.71

High

105

Argus

Buy

downgrade

$91 -> $90

AI Analysis

2026-01-28

Reason

Argus

Price Target

$91 -> $90

AI Analysis

2026-01-28

downgrade

Buy

Reason

Argus lowered the firm's price target on CVS Health to $90 from $91 but keeps a Buy rating on the shares. The stock declined by close to 15% after the Centers for Medicare and Medicaid Services proposed a flat 2027 Medicare Advantage reimbursement rate over 2026, but the firm sees this rate as likely to be revised upward before final implementation in April 2026, the analyst tells investors in a research note, adding that should the final rate increase come in lower than the prior year's 5.1% increase, CVS's diversification should be able to mitigate the impact compared to pure play health insurers.

BofA

Buy

maintain

$100 -> $95

2026-01-27

Reason

BofA

Price Target

$100 -> $95

2026-01-27

maintain

Buy

Reason

BofA lowered the firm's price target on CVS Health to $95 from $100 and keeps a Buy rating on the shares after the Centers for Medicare & Medicaid Services announced the proposed policies in the calendar year 2027 Advance Notice are projected to result in a net all-in rate of 2.54%, below the market's general expectation for an increase of 4%-6%. The announcement is a headwind to the Medicare Advantage margin expansion story, says the analyst, who estimates the gross unmitigated headwind to CVS would be more than $1B of Medicare Advantage revenue and margin if the final rates match these advanced rates and CVS makes no offsetting changes to benefits. However, the firm also notes that in the past 14 years, the final rate has come in better than the proposal 64% of the time.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CVS

Unlock Now

CVS Should I Buy

CVS Should I Buy

Should You Buy CVS Health Corp (CVS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch